PL3098239T3 - Wektor z dwuniciowym rna ukierunkowany na egfr do ogólnoustrojowego leczenia nowotworu - Google Patents

Wektor z dwuniciowym rna ukierunkowany na egfr do ogólnoustrojowego leczenia nowotworu

Info

Publication number
PL3098239T3
PL3098239T3 PL16177258T PL16177258T PL3098239T3 PL 3098239 T3 PL3098239 T3 PL 3098239T3 PL 16177258 T PL16177258 T PL 16177258T PL 16177258 T PL16177258 T PL 16177258T PL 3098239 T3 PL3098239 T3 PL 3098239T3
Authority
PL
Poland
Prior art keywords
homing
egfr
double
stranded rna
cancer treatment
Prior art date
Application number
PL16177258T
Other languages
English (en)
Inventor
Alexander Levitzki
Alexei Shir
Original Assignee
Targimmune Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targimmune Therapeutics Ag filed Critical Targimmune Therapeutics Ag
Publication of PL3098239T3 publication Critical patent/PL3098239T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Information Transfer Between Computers (AREA)
  • Peptides Or Proteins (AREA)
PL16177258T 2008-12-22 2009-12-22 Wektor z dwuniciowym rna ukierunkowany na egfr do ogólnoustrojowego leczenia nowotworu PL3098239T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13969808P 2008-12-22 2008-12-22
EP09806144.3A EP2379597B8 (en) 2008-12-22 2009-12-22 Egfr-homing double-stranded rna vector for systemic cancer treatment
EP16177258.7A EP3098239B1 (en) 2008-12-22 2009-12-22 Egfr-homing double-stranded rna vector for systemic cancer treatment
PCT/IL2009/001210 WO2010073247A2 (en) 2008-12-22 2009-12-22 Egfr-homing double-stranded rna vector for systemic cancer treatment

Publications (1)

Publication Number Publication Date
PL3098239T3 true PL3098239T3 (pl) 2020-04-30

Family

ID=42104511

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16177258T PL3098239T3 (pl) 2008-12-22 2009-12-22 Wektor z dwuniciowym rna ukierunkowany na egfr do ogólnoustrojowego leczenia nowotworu

Country Status (20)

Country Link
US (2) US9006406B2 (pl)
EP (3) EP2379597B8 (pl)
JP (1) JP2012513210A (pl)
CN (1) CN102325794A (pl)
AU (1) AU2009332522A1 (pl)
BR (1) BRPI0922985A2 (pl)
CA (1) CA2748125A1 (pl)
CY (1) CY1123371T1 (pl)
DK (2) DK3098239T3 (pl)
ES (2) ES2602753T3 (pl)
HR (1) HRP20192317T1 (pl)
HU (1) HUE047759T2 (pl)
IL (1) IL213739A0 (pl)
LT (1) LT3098239T (pl)
MX (1) MX2011006720A (pl)
PL (1) PL3098239T3 (pl)
PT (1) PT3098239T (pl)
SI (1) SI3098239T1 (pl)
SM (1) SMT202000038T1 (pl)
WO (1) WO2010073247A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201406208QA (en) * 2012-05-03 2014-11-27 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
JP6103832B2 (ja) 2012-06-25 2017-03-29 Hoya株式会社 Ｅｇｆｒ結合性ペプチド
US9431064B2 (en) * 2012-11-02 2016-08-30 Taiwan Semiconductor Manufacturing Company, Ltd. Memory circuit and cache circuit configuration
US10796320B2 (en) * 2013-12-23 2020-10-06 Mastercard International Incorporated Systems and methods for passively determining a ratio of purchasers and prospective purchasers in a merchant location
US10278991B2 (en) 2014-05-14 2019-05-07 Targimmune Therapeutics Ag Polyethyleneimine polyethyleneglycol vectors
EP3274840A4 (en) * 2015-03-27 2018-12-26 Intel Corporation Dynamic cache allocation
PT3319587T (pt) * 2015-11-17 2019-11-20 Bioncotech Therapeutics S L Nova composição farmacêutica que compreende partículas compreendendo um complexo de um polirribonuleótido de cadeia dupla e uma polialquilenoimina
GB201601868D0 (en) * 2016-02-02 2016-03-16 Lytix Biopharma As Methods
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
WO2018042411A1 (en) * 2016-09-04 2018-03-08 Alex Levitzki Management And Holdings, Ltd. Chimeric proteins for targeting dsrna
JP2020520368A (ja) * 2017-05-17 2020-07-09 ビオンコテック セラピューティクス エセ．エレ 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
EP3688008A1 (en) * 2017-09-27 2020-08-05 TargImmune Therapeutics AG Castration resistant prostate cancer
KR20210087949A (ko) 2018-11-01 2021-07-13 알파 타우 메디컬 리미티드 종양내 알파-방출체 방사선 및 세포내 병원체에 대한 세포질 센서의 활성화
SG11202109274TA (en) * 2019-04-03 2021-10-28 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
WO2020263770A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Nucleic acid compositions including a polyalkyleneimine-alkoxylene polymer and methods of making and using the same
WO2020263776A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Nucleic acid compositions including a polyalkyleneimine-alkoxylene polymer and methods of making and using the same
US10915418B1 (en) 2019-08-29 2021-02-09 Snowflake Inc. Automated query retry in a database environment
IL320618A (en) 2022-11-07 2025-07-01 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
WO2025238236A1 (en) 2024-05-16 2025-11-20 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045491A2 (en) 2002-11-18 2004-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Targeted double stranded rna mediated cell killing
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7937291B2 (en) * 2009-04-22 2011-05-03 Visa U.S.A. Inc. Providing an announcement about transactions of a target merchant to a consumer

Also Published As

Publication number Publication date
MX2011006720A (es) 2011-10-06
LT3098239T (lt) 2020-02-10
HUE047759T2 (hu) 2020-05-28
CY1123371T1 (el) 2021-10-29
EP3098239B1 (en) 2019-10-23
US9006406B2 (en) 2015-04-14
US20120021006A1 (en) 2012-01-26
EP3098239A1 (en) 2016-11-30
CN102325794A (zh) 2012-01-18
WO2010073247A3 (en) 2010-08-19
ES2764396T3 (es) 2020-06-03
ES2602753T3 (es) 2017-02-22
AU2009332522A1 (en) 2011-08-11
EP3705493A1 (en) 2020-09-09
DK2379597T3 (en) 2016-12-05
SI3098239T1 (sl) 2020-03-31
BRPI0922985A2 (pt) 2016-10-04
JP2012513210A (ja) 2012-06-14
WO2010073247A2 (en) 2010-07-01
EP2379597B8 (en) 2016-11-30
EP2379597A2 (en) 2011-10-26
SMT202000038T1 (it) 2020-03-13
DK3098239T3 (da) 2020-01-20
CA2748125A1 (en) 2010-07-01
HRP20192317T1 (hr) 2020-03-20
PT3098239T (pt) 2020-01-15
EP2379597B1 (en) 2016-08-10
IL213739A0 (en) 2011-07-31
US20120330998A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
HUE047759T2 (hu) EGFR vándorlást elõsegítõ, kettõs szálú RNS vektor rák szisztémás kezelésére
GB2470672B (en) Methods of RNA amplification in the presence of DNA
TWI370740B (en) Immunostimulatory oligonucleotides
GB0821457D0 (en) Oligonucleotides
PT2294200E (pt) Novos genes envolvidos em biossíntese
GB0800702D0 (en) Genes
IL208374A0 (en) Double-stranded lipid-modified rna having high rna interference effect
IL238394A0 (en) Cancer treatment method
GB0804496D0 (en) Treating cancer
EP2253323A4 (en) ANTIALLERGENIC ACTIVE SUBSTANCE
GB0918722D0 (en) Anti cancer agent
EP2144888A4 (en) METHODS OF TREATING CANCER
EP2321641A4 (en) GENE METHYLATION IN THE DIAGNOSIS OF CANCER
GB0707556D0 (en) Treatment for cancer
GB0809046D0 (en) Cancer treatment
IL213735A0 (en) Egfr-homing double-stranded rna vector for systemic cancer treatment
GB0903562D0 (en) RNA molecules
GB0702681D0 (en) DNA-based biosensors
AU2008903338A0 (en) Ore Treatment Means
GB0809627D0 (en) Targeted gene therapy
GB0813213D0 (en) Anti cancer agent
GB0808587D0 (en) Anti cancer agents
GB0723503D0 (en) Cancer treatment
GB0700493D0 (en) Cancer treatment
GB0807637D0 (en) Enzymatic cancer target genes